Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
OY3 (PYP-TC99M ATRIAL AMYLOIDOSIS) CANNOT BE LOCATED ON THE PRICE SCHEDULE FOUND THAT THIS ITEM WAS INADVERTENTLY LEFT OFF THE PRICE LIST is a federal award for 250-Network Contract Office 10 (36C250) held by Schaaf Drugs, LLC. Estimated value $605K ($119K obligated). Current period of performance ends Jan 5, 2027 (potential Jan 5, 2028). Place of performance: LIMA OH.
OY3 (PYP-TC99M ATRIAL AMYLOIDOSIS) CANNOT BE LOCATED ON THE PRICE SCHEDULE FOUND THAT THIS ITEM WAS INADVERTENTLY LEFT OFF THE PRICE LIST
Recompete timing
PublicCurrent PoP ends Jan 5, 2027 (100 days remaining). Agencies typically plan 12–18 months ahead — at 3.3 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 36C25026N0185? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordSchaaf Drugs, LLC — $3.7M obligated across 18 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C25026N0185?
36C25026N0185 (Oy3 (pyp-tc99m ATRIAL amyloidosis) CANNOT BE) is a 250-Network Contract Office 10 (36C250) award with a potential value of $605K, currently held by Schaaf Drugs, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C250-26-N-0185?
36C250-26-N-0185 is the dashed form of PIID 36C25026N0185 (Oy3 (pyp-tc99m ATRIAL amyloidosis) CANNOT BE), held by Schaaf Drugs, LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C25026N0185?
250-Network Contract Office 10 (36C250) awarded 36C25026N0185 to Schaaf Drugs, LLC (potential $605K).
Who is the incumbent on 36C25026N0185?
Schaaf Drugs, LLC is the incumbent with $3.7M across 18 related awards in SCOUT’s public footprint. The current period of performance ends Jan 5, 2027.
When does Schaaf Drugs, LLC’s 36C25026N0185 come up for recompete?
SCOUT tracks a period-of-performance end of Jan 5, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C25026N0185? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.